CG Oncology (CGON) said Friday it has sped up the timeline for the topline data readout of the phase 3 clinical trial of adjuvant intravesical cretostimogene grenadenorepvec versus surveillance in patients with intermediate-risk non-muscle invasive bladder cancer to H1 2026, nearly a year ahead of schedule because of early enrollment of 360 patients.

Chairman and Chief Executive Arthur Kuan said the company hopes to bring forward a potential indication for cretostimogene, an investigational immunotherapy, as a treatment for non-muscle bladder cancer.

Shares of the company were up over 6% in recent premarket activity Friday.